Ben F. Brian

Ben F. Brian

Auto-generated profile, based on publicly available information

Ben F. Brian

KEMRI Graduate School, Kenya Medical Research Institute, Jomo Kenyatta University of Agriculture and Technology, Kenya

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in Endocrinology
Verified
Journal Article
Open access
PDF file
BBBen F Brian
Ben F Brian
TFTanya S Freedman
Tanya S Freedman
Effective regulation of immune-cell activation is critical for ensuring that the immune response, and inflammation generated for the purpose of pathogen elimination, are limited in space and time to minimize tissue damage. Autoimmune disease can occur when immunoreceptor signaling is dysregulated, leading to unrestrained inflammation and organ damage. Conversely, tumors can coopt the tissue healing and immunosuppressive functions of hematopoietic cells to promote metastasis and evade therapy. The Src-family kinase Lyn is an essential regulator of immunoreceptor signaling, initiating both proinflammatory and suppressive signaling pathways in myeloid immune cells (eg, neutrophils, dendritic cells, monocytes, macrophages) and in B lymphocytes. Defects in Lyn signaling are implicated in autoimmune disease, but mechanisms by which Lyn, expressed along with a battery of other Src-family kinases, may uniquely direct both positive and negative signaling remain incompletely defined. This review describes our current understanding of the activating and inhibitory contributions of Lyn to immunoreceptor signaling and how these processes contribute to myeloid and B-cell function. We also highlight recent work suggesting that the 2 proteins generated by alternative splicing of lyn, LynA and LynB, differentially regulate both immune and cancer-cell signaling. These principles may also extend to other Lyn-expressing cells, such as neuronal and endocrine cells. Unraveling the common and cell-specific aspects of Lyn function could lead to new approaches to therapeutically target dysregulated pathways in pathologies ranging from autoimmune and neurogenerative disease to cancer.

22 April 2022 in Science Advances
Verified
Journal Article
Open access
BBBen F. Brian
Ben F. Brian
MSMonica L. Sauer
Monica L. Sauer
JGJoseph T. Greene
Joseph T. Greene
SSS. Erandika Senevirathne
S. Erandika Senevirathne
ALAnders J. Lindstedt
Anders J. Lindstedt
TFTanya S. Freedman
Tanya S. Freedman
Here, we report that the LynB splice variant of the Src-family kinase Lyn exerts a dominant immunosuppressive function in vivo, whereas the LynA isoform is uniquely required to restrain autoimmunity in female mice. We used CRISPR-Cas9 gene editing to constrain lyn splicing and expression, generating single-isoform LynA knockout (LynA KO ) or LynB KO mice. Autoimmune disease in total Lyn KO mice is characterized by production of antinuclear antibodies, glomerulonephritis, impaired B cell development, and overabundance of activated B cells and proinflammatory myeloid cells. Expression of LynA or LynB alone uncoupled the developmental phenotype from the autoimmune disease: B cell transitional populations were restored, but myeloid cells and differentiated B cells were dysregulated. These changes were isoform-specific, sexually dimorphic, and distinct from the complete Lyn KO . Despite the apparent differences in disease etiology and penetrance, loss of either LynA or LynB had the potential to induce severe autoimmune disease with parallels to human systemic lupus erythematosus (SLE).

4 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
BBBen F. Brian
Ben F. Brian
MSMonica L. Sauer
Monica L. Sauer
BRBrian Ruis
Brian Ruis
JAJennifer L. Auger
Jennifer L. Auger
SSS. Erandika Senevirathne
S. Erandika Senevirathne
TFTanya S. Freedman
Tanya S. Freedman
The unique roles of the Src-family kinases LynA and LynB in immune activating and inhibitory signaling have eluded definition. Here we report that LynB, the shorter splice product of lyn , carries the dominant immunosuppressive function. We used CRISPR/Cas9 gene editing to constrain lyn splicing and expression to a single product: LynA KO or LynB KO mice. While activities of both isoforms regulate homeostatic Lyn expression, only LynB protects against autoimmune disease. LynB KO monocytes and dendritic cells are TLR4-hyper-responsive, and TLR4 expression increases with age in LynB KO myeloid and B cells. These changes are accompanied by the development of an inflammatory disease that resembles human systemic lupus erythematosus (SLE). The interplay between LynB and TLR4 likely underlies the autoimmunity risk associated with LYN hypomorph and TLR4 hypermorph alleles.

1 April 2023 in ACTA SCIENTIFIC MICROBIOLOGY
Verified
Journal Article
Open access
SKSa Kuve
Sa Kuve
JOJacob O Ouko
Jacob O Ouko
SKSusan Kiiru
Susan Kiiru
DWDan Waithiru
Dan Waithiru
BBBen Brian
Ben Brian
JMJn Mwaniki
Jn Mwaniki

14 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BBBen F. Brian
Ben F. Brian
FSFrances V. Sjaastad
Frances V. Sjaastad
TFTanya S. Freedman
Tanya S. Freedman
The kinase Csk is the primary negative regulator of the Src-family kinases (SFKs, e.g., Lck, Fyn, Lyn, Hck, Fgr, Blk, Yes), phosphorylating a tyrosine on the SFK C-terminal tail that mediates autoinhibition. Csk also binds phosphatases, including PTPN12 (PTP-PEST) and immune-cell PTPN22 (LYP/Pep), which dephosphorylate the SFK activation loop to promote autoinhibition. Csk-binding proteins (e.g., CBP/PAG1) oligomerize within membrane microdomains, and high local concentration promotes Csk function. Purified Csk homodimerizes in solution through an interface that overlaps the phosphatase binding footprint. Here we demonstrate that Csk can homodimerize in Jurkat T cells, in competition with PTPN22 binding. We designed SH3-domain mutations in Csk that selectively impair homodimerization (H21I) or PTPN22 binding (K43D) and verified their kinase activity in solution. Disruption of either interaction, however, decreased the negative-regulatory function of Csk in cells. Csk W47A, a substitution previously reported to block PTPN22 binding, also impairs homodimerization. Csk H21I and K43D will be useful tools for dissecting the protein-specific drivers of autoimmunity mediated by the human polymorphism PTPN22 R620W, which impairs interaction with Csk and with the E3 ubiquitin ligase TRAF3. Future investigations of Csk homodimer activity and phosphatase interactions may reveal new facets of SFK regulation in hematopoietic and non-hematopoietic cells.